Future Science Group
Browse
supplementary_material.docx (21.43 kB)
Download file

Supplementary Material – Phase II, Clinical Trial of Cabozantinib for the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplant

Download (21.43 kB)
dataset
posted on 2022-03-15, 08:51 authored by Figshare Future Science GroupFigshare Future Science Group, Amirhossein Azhie, Robert C. Grant, Michael Herman, Lisa Wang, Jennifer J. Knox, Mamatha Bhat

Allowed Therapies

Prohibited or Restricted Therapies

Biological specimens (Plans for collection, laboratory evaluation, and storage of specimens)

Confidentiality

Retention of Patient Records and Study Files

Funding

Ipsen

History

Usage metrics

    Future OncologyFuture Oncology

    Categories

    Keywords

    recurrent HCCliver transplantationcabozantinibmulti kinase inhibitorsCancer Therapy (excl. Chemotherapy and Radiation Therapy)

    Licence

    CC BY-NC-ND 4.0

    Exports